Clinical Trials
2 trialsNCT04284774 2026-05-27
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02383927 2024-07-11
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Kura Oncology, Inc.
Phase 2 Completed